Klaus Seppi
#154,518
Most Influential Person Now
Klaus Seppi's AcademicInfluence.com Rankings
Klaus Seppiphilosophy Degrees
Philosophy
#8686
World Rank
#12111
Historical Rank
Logic
#5715
World Rank
#7137
Historical Rank
Klaus Seppibiology Degrees
Biology
#11815
World Rank
#15240
Historical Rank
Neuroscience
#1944
World Rank
#2000
Historical Rank
Download Badge
Philosophy Biology
Klaus Seppi's Degrees
- Doctorate Medicine University of Vienna
- PhD Neuroscience University of Vienna
Why Is Klaus Seppi Influential?
(Suggest an Edit or Addition)Klaus Seppi's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Second consensus statement on the diagnosis of multiple system atrophy (2008) (2532)
- Parkinson disease (2017) (1821)
- Clinical diagnosis of progressive supranuclear palsy: The movement disorder society criteria (2017) (1150)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the non‐motor symptoms of Parkinson's disease (2011) (1005)
- A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease. (2011) (778)
- International Parkinson and movement disorder society evidence‐based medicine review: Update on treatments for the motor symptoms of Parkinson's disease (2018) (497)
- The Movement Disorder Society Evidence‐Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease (2011) (493)
- Update on treatments for nonmotor symptoms of Parkinson's disease—an evidence‐based medicine review (2019) (492)
- Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS) (2004) (443)
- The Onset of Nonmotor Symptoms in Parkinson's disease (The ONSET PD Study) (2015) (405)
- The natural history of multiple system atrophy: a prospective European cohort study (2013) (376)
- Decreased striatal dopamine transporter uptake and substantia nigra hyperechogenicity as risk markers of synucleinopathy in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study (2010) (360)
- EFNS/MDS‐ES recommendations for the diagnosis of Parkinson's disease (2013) (355)
- Restless legs syndrome (2005) (266)
- Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease (2002) (264)
- Prevalence of movement disorders in men and women aged 50–89 years (Bruneck Study cohort): a population-based study (2005) (257)
- Seminar on choreas (2006) (246)
- Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. (2002) (240)
- Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy (2003) (237)
- The Parkinson's progression markers initiative (PPMI) – establishing a PD biomarker cohort (2018) (234)
- Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD (2002) (233)
- Presentation, diagnosis, and management of multiple system atrophy in Europe: Final analysis of the European multiple system atrophy registry (2010) (212)
- Identification of genetic variants associated with Huntington's disease progression: a genome-wide association study (2017) (208)
- Red flags for multiple system atrophy (2008) (198)
- Cognitive impairment in multiple system atrophy: A position statement by the neuropsychology task force of the MDS multiple system atrophy (MODIMSA) study group (2014) (193)
- Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome (2005) (193)
- White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: A diffusion‐tensor imaging and voxel‐based morphometry study (2011) (186)
- The Concept of Prodromal Parkinson’s Disease (2015) (185)
- Long‐term antidyskinetic efficacy of amantadine in Parkinson's disease (2010) (183)
- Grading of neuropathology in multiple system atrophy: Proposal for a novel scale (2005) (166)
- Voxel‐based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy (2003) (165)
- Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD (2015) (164)
- Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons. (2011) (159)
- Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial) (2010) (155)
- Prevalence and Burden of Gait Disorders in Elderly Men and Women Aged 60–97 Years: A Population-Based Study (2013) (154)
- Validation of the MDS clinical diagnostic criteria for Parkinson's disease (2018) (153)
- Trace of diffusion tensor differentiates the Parkinson variant of multiple system atrophy and Parkinson's disease (2004) (152)
- Magnetic resonance imaging for the diagnosis of Parkinson’s disease (2017) (149)
- Proposed neuroimaging criteria for the diagnosis of multiple system atrophy (2009) (143)
- Dopamine transporter imaging deficit predicts early transition to synucleinopathy in idiopathic rapid eye movement sleep behavior disorder (2017) (138)
- Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. (2006) (134)
- Voxel based morphometry reveals a distinct pattern of frontal atrophy in progressive supranuclear palsy (2004) (133)
- Voxel based morphometry reveals specific gray matter changes in primary dystonia (2007) (129)
- Differentiation of malignant and benign musculoskeletal tumors: combined color and power Doppler US and spectral wave analysis. (2002) (128)
- Visualization of nigrosome 1 and its loss in PD: Pathoanatomical correlation and in vivo 7T MRI (2014) (127)
- The prevalence of primary dystonia in the general community (2002) (125)
- Soluble Receptor Activator of Nuclear Factor-&kgr;B Ligand and Risk for Cardiovascular Disease (2007) (125)
- Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. (2005) (124)
- Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease (2013) (119)
- The PRIPS study: screening battery for subjects at risk for Parkinson's disease (2013) (118)
- Dorsolateral nigral hyperintensity on 3.0T susceptibility‐weighted imaging in neurodegenerative Parkinsonism (2015) (114)
- Progression of brain atrophy in multiple system atrophy (2007) (112)
- Progression of multiple system atrophy (MSA): A prospective natural history study by the European MSA Study Group (EMSA SG) (2006) (112)
- Meta‐analysis of dorsolateral nigral hyperintensity on magnetic resonance imaging as a marker for Parkinson's disease (2017) (111)
- Significance of MRI in Diagnosis and Differential Diagnosis of Parkinson’s Disease (2010) (105)
- Enteric nervous system α-synuclein immunoreactivity in idiopathic REM sleep behavior disorder (2015) (104)
- Mortality in Parkinson's disease: A 38‐year follow‐up study (2015) (104)
- Health‐related quality of life in multiple system atrophy (2006) (101)
- Neurological outcome and quality of life 3 months after COVID‐19: A prospective observational cohort study (2020) (101)
- Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. (2017) (99)
- An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism (2005) (99)
- Polycystic ovaries, obesity and insulin resistance in women with epilepsy (2002) (98)
- Diffusion weighted imaging best discriminates PD from MSA‐P: A comparison with tilt table testing and heart MIBG scintigraphy (2007) (96)
- Movement disorder society criteria for clinically established early Parkinson's disease (2018) (96)
- Progression of putaminal degeneration in multiple system atrophy: A serial diffusion MR study (2006) (94)
- Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. (2010) (93)
- Three new cases of late-onset cblC defect and review of the literature illustrating when to consider inborn errors of metabolism beyond infancy (2014) (92)
- Subacute dementia and imaging correlates in a case of Fahr’s disease (2004) (91)
- Midbrain hyperechogenicity in idiopathic REM sleep behavior disorder (2009) (91)
- Diagnostic value of the REM sleep behavior disorder screening questionnaire in Parkinson's disease. (2015) (87)
- Left hemispheric predominance of nigrostriatal dysfunction in Parkinson's disease. (2012) (87)
- The Movement Disorder Society Criteria for the Diagnosis of Multiple System Atrophy (2022) (84)
- Comparison of diffusion‐weighted imaging and [123I]IBZM‐SPECT for the differentiation of patients with the Parkinson variant of multiple system atrophy from those with Parkinson's disease (2004) (84)
- Probable RBD and association with neurodegenerative disease markers: A population‐based study (2015) (83)
- Non-alcoholic fatty liver disease (NAFLD), insulin resistance and lipid profile in antiepileptic drug treatment (2009) (83)
- Video‐EEG monitoring: Safety and adverse events in 507 consecutive patients (2011) (82)
- International Guidelines for the Treatment of Huntington's Disease (2019) (79)
- Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate (2002) (79)
- Riluzole in Huntington's disease (HD): an open label study with one year follow up (2001) (79)
- Diagnostic potential of automated subcortical volume segmentation in atypical parkinsonism (2016) (78)
- The European Multiple System Atrophy-Study Group (EMSA-SG) (2005) (78)
- Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study (2006) (78)
- Loss of dorsolateral nigral hyperintensity on 3.0 tesla susceptibility‐weighted imaging in idiopathic rapid eye movement sleep behavior disorder (2016) (78)
- Increased daytime sleepiness in Parkinson's disease: A questionnaire survey (2003) (77)
- Efficacy of rasagiline in patients with the parkinsonian variant of multiple system atrophy: a randomised, placebo-controlled trial (2015) (76)
- Motoric cognitive risk syndrome: Multicenter incidence study (2015) (75)
- Cause‐specific mortality among patients with epilepsy: Results from a 30‐year cohort study (2013) (75)
- Which dyskinesia scale best detects treatment response? (2013) (75)
- A novel grading scale for striatonigral degeneration (multiple system atrophy) (2002) (74)
- The role of high‐field magnetic resonance imaging in parkinsonian disorders: Pushing the boundaries forward (2017) (74)
- Predictors of Survival in Dementia with Lewy Bodies and Parkinson Dementia (2007) (74)
- Decision making under risk and under ambiguity in Parkinson's disease (2009) (73)
- Prevalence of Primary Headaches and Cranial Neuralgias in Men and Women Aged 55–94 Years (Bruneck Study) (2009) (73)
- Topography of putaminal degeneration in multiple system atrophy: A diffusion magnetic resonance study (2006) (73)
- Prodromal Parkinson's disease as defined per MDS research criteria in the general elderly community (2016) (72)
- Genome-wide association study in essential tremor identifies three new loci (2016) (70)
- Five‐year follow‐up of substantia nigra echogenicity in idiopathic REM sleep behavior disorder (2014) (69)
- Diagnostic accuracy of the magnetic resonance Parkinsonism index and the midbrain‐to‐pontine area ratio to differentiate progressive supranuclear palsy from Parkinson's disease and the Parkinson variant of multiple system atrophy (2010) (68)
- Cortical atrophy in the cerebellar variant of multiple system atrophy: A voxel‐based morphometry study (2006) (68)
- Sniffing the diagnosis: Olfactory testing in neurodegenerative parkinsonism. (2017) (67)
- Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease (2001) (67)
- Mortality in Parkinson's disease: A 20‐year follow‐up study (2009) (66)
- Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. (2006) (64)
- Urinary albumin excretion is independently associated with carotid and femoral artery atherosclerosis in the general population. (2005) (63)
- Botulinum toxin treatment in atypical parkinsonian disorders associated with disabling focal dystonia (2002) (63)
- Differences in MDS‐UPDRS Scores Based on Hoehn and Yahr Stage and Disease Duration (2016) (63)
- Social and clinical determinants of quality of life in Parkinson’s disease in Austria: a cohort study (2010) (62)
- Apomorphine for Parkinson’s Disease: Efficacy and Safety of Current and New Formulations (2019) (62)
- Treatment options for depression and psychosis in Parkinson's disease (2001) (62)
- Alpha-synuclein seeds in olfactory mucosa of patients with isolated REM sleep behaviour disorder. (2021) (60)
- Restless legs syndrome in Parkinson's disease (2009) (60)
- Orthostatic hypotension and attention in Parkinson’s disease with and without dementia (2007) (59)
- Prevalence and Associated Factors of Sarcopenia and Frailty in Parkinson’s Disease: A Cross-Sectional Study (2018) (59)
- A critique of the second consensus criteria for multiple system atrophy (2019) (59)
- Characterizing advanced Parkinson’s disease: OBSERVE-PD observational study results of 2615 patients (2019) (57)
- Correlation of dopaminergic terminal dysfunction and microstructural abnormalities of the basal ganglia and the olfactory tract in Parkinson's disease. (2013) (57)
- Progression of parkinsonism in multiple system atrophy (2005) (56)
- The reorganization of functional architecture in the early-stages of Parkinson's disease. (2018) (55)
- Cause-specific mortality in adult epilepsy patients from Tyrol, Austria: hospital-based study (2014) (54)
- Update on diffusion MRI in Parkinson's disease and atypical parkinsonism (2013) (53)
- Safety and efficacy of pridopidine in patients with Huntington's disease (PRIDE-HD): a phase 2, randomised, placebo-controlled, multicentre, dose-ranging study (2019) (53)
- Mortality in Parkinson's disease, a 20‐year follow‐up study (2009) (53)
- How to diagnose MSA early: the role of magnetic resonance imaging (2005) (52)
- Performance of the Movement Disorders Society criteria for prodromal Parkinson's disease: A population‐based 10‐year study (2018) (51)
- Potential of advanced MR imaging techniques in the differential diagnosis of parkinsonism (2009) (51)
- Enlarged hyperechogenic substantia nigra is related to motor performance and olfaction in the elderly (2010) (50)
- Abnormalities of dopaminergic neurotransmission in SCA2: A combined 123I‐βCIT and 123I‐IBZM SPECT study (2004) (50)
- Genetic analysis of candidate genes modifying the age-at-onset in Huntington’s disease (2006) (50)
- Clinical and neuropathological correlates of Lewy body disease (2003) (50)
- Free water improves detection of changes in the substantia nigra in parkinsonism: A multisite study (2017) (49)
- Diffusion imaging of nigral alterations in early Parkinson's disease with dopaminergic deficits (2015) (48)
- The diagnostic accuracy of the hummingbird and morning glory sign in patients with neurodegenerative parkinsonism. (2018) (47)
- Non‐Motor Symptoms in Parkinson's Disease are Reduced by Nabilone (2020) (47)
- Basal forebrain atrophy is a distinctive pattern in dementia with Lewy bodies (2004) (47)
- Freezing of gait in postmortem‐confirmed atypical parkinsonism (2002) (47)
- Relationship between the MDS-UPDRS and Quality of Life: A large multicenter study of 3206 patients. (2018) (47)
- Transient restless legs syndrome after spinal anesthesia (2002) (46)
- Optimizing odor identification testing as quick and accurate diagnostic tool for Parkinson's disease (2016) (44)
- Brain structural profile of multiple system atrophy patients with cognitive impairment (2017) (44)
- Diffusion‐weighted imaging in Huntington's disease (2006) (43)
- Risk factors and prodromal markers and the development of Parkinson’s disease (2013) (41)
- Speech Biomarkers in Rapid Eye Movement Sleep Behavior Disorder and Parkinson Disease (2021) (41)
- Alpha-synuclein immunoreactivity patterns in the enteric nervous system (2015) (40)
- Parkinsonism following striatal infarcts: incidence in a prospective stroke unit cohort (2004) (40)
- White and gray matter abnormalities in narcolepsy with cataplexy. (2012) (40)
- Diffusion-weighted MRI distinguishes Parkinson disease from the parkinsonian variant of multiple system atrophy: A systematic review and meta-analysis (2017) (40)
- The clinical spectrum of levodopa-induced motor complications (2010) (39)
- MR planimetry in neurodegenerative parkinsonism yields high diagnostic accuracy for PSP. (2018) (39)
- Differentiation of SCA2 from MSA‐C using proton magnetic resonance spectroscopic imaging (2007) (39)
- Parkinson's disease and arithmetics: The role of executive functions (2006) (37)
- Progression of dopamine transporter decline in patients with the Parkinson variant of multiple system atrophy: a voxel-based analysis of [123I]β-CIT SPECT (2012) (37)
- Nonmotor Symptoms in Subjects Without Evidence of Dopaminergic Deficits (2015) (36)
- Towards translational therapies for multiple system atrophy (2014) (36)
- Elastic Abdominal Binders Attenuate Orthostatic Hypotension in Parkinson's Disease (2016) (36)
- Seeing ophthalmologic problems in Parkinson disease (2020) (34)
- No functional effects of embryonic neuronal grafts on motor deficits in a 3-nitropropionic acid rat model of advanced striatonigral degeneration (multiple system atrophy) (2001) (34)
- Sensor‐based gait analysis in atypical parkinsonian disorders (2018) (33)
- Cannabinoids for Treatment of Dystonia in Huntington's Disease. (2018) (33)
- Progression of dysautonomia in multiple system atrophy: a prospective study of self‐perceived impairment (2007) (33)
- Substantia Nigra Hyperechogenicity as a Marker for Parkinson's Disease: A Population-Based Study (2013) (32)
- The influence of deep brain stimulation on pain perception in Parkinson's disease (2011) (31)
- Computerized Tremor Analysis of Valproate‐induced Tremor: A Comparative Study of Controlled‐release versus Conventional Valproate (2005) (31)
- Deep brain stimulation in Huntington's disease: A 4‐year follow‐up case report (2012) (31)
- Cerebrospinal fluid hypocretin‐1 levels in multiple system atrophy (2007) (30)
- Placebo‐controlled trial of riluzole in multiple system atrophy (2006) (30)
- Automated MRI Classification in Progressive Supranuclear Palsy: A Large International Cohort Study (2020) (29)
- Structural Imaging in Atypical Parkinsonism. (2018) (29)
- Predictors for mild parkinsonian signs: a prospective population-based study. (2015) (28)
- Riluzole therapy in cervical dystonia (2002) (28)
- Is Transcranial Sonography Useful to Distinguish Scans Without Evidence of Dopaminergic Deficit Patients From Parkinson's Disease? (2012) (28)
- Auditory startle response in cervical dystonia (2003) (28)
- Coil embolization of internal mammary artery injured during central vein catheter and cardiac pacemaker lead insertion. (2009) (28)
- Neuroimaging: Current role in detecting pre‐motor Parkinson's disease (2012) (28)
- A novel computer-assisted image analysis of [123I]β-CIT SPECT images improves the diagnostic accuracy of parkinsonian disorders (2011) (27)
- An open trial of levetiracetam for segmental and generalized dystonia (2007) (27)
- The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach (2016) (27)
- Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System (2019) (26)
- Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes (2003) (26)
- Serial contrast-enhanced magnetic resonance imaging and spectroscopic imaging of acute multiple sclerosis lesions under high-dose methylprednisolone therapy (2003) (26)
- Prognosis and prognostic factors in non‐traumatic acute‐onset compressive mononeuropathies – radial and peroneal mononeuropathies (2013) (25)
- Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. (2019) (24)
- NMDA receptor gene variations as modifiers in Huntington disease: a replication study (2011) (24)
- Morphometric MRI profiles of multiple system atrophy variants and implications for differential diagnosis (2019) (23)
- Levodopa‐induced sleepiness in the Parkinson variant of multiple system atrophy (2006) (23)
- An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes (2012) (23)
- MRI for the differential diagnosis of neurodegenerative parkinsonism in clinical practice. (2007) (23)
- Multiple system atrophy as emerging template for accelerated drug discovery in α-synucleinopathies (2014) (22)
- Recommendations of the Global Multiple System Atrophy Research Roadmap Meeting (2018) (22)
- Augmentation and impulsive behaviors in restless legs syndrome (2016) (22)
- Neurological outcomes 1 year after COVID‐19 diagnosis: A prospective longitudinal cohort study (2022) (22)
- Early distinction of Parkinson‐variant multiple system atrophy from Parkinson's disease (2019) (21)
- Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study (2012) (20)
- Midbrain hyperechogenicity, hyposmia, mild parkinsonian signs and risk for incident Parkinson's disease over 10 years: A prospective population-based study. (2019) (20)
- Cognition in multiple system atrophy: a single‐center cohort study (2020) (20)
- Diagnostic potential of dentatorubrothalamic tract analysis in progressive supranuclear palsy. (2018) (20)
- Gait and postural disorders in parkinsonism: a clinical approach (2019) (20)
- A follow‐up study of substantia nigra echogenicity in healthy adults (2012) (19)
- Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. (2019) (19)
- European Academy of Neurology/Movement Disorder Society‐European Section Guideline on the Treatment of Parkinson's Disease: I. Invasive Therapies (2022) (19)
- Association of transient orthostatic hypotension with falls and syncope in patients with Parkinson disease (2020) (19)
- Pramipexole extended release in Parkinson’s disease (2011) (19)
- A New MRI Measure to Early Differentiate Progressive Supranuclear Palsy From De Novo Parkinson's Disease in Clinical Practice: An International Study (2020) (19)
- Can Autonomic Testing and Imaging Contribute to the Early Diagnosis of Multiple System Atrophy? A Systematic Review and Recommendations by the Movement Disorder Society Multiple System Atrophy Study Group (2020) (19)
- Drug safety evaluation of rotigotine (2012) (19)
- Irresistible onset of sleep during acute levodopa challenge in a patient with multiple system atrophy (MSA): Placebo‐controlled, polysomnographic case report (2001) (18)
- Nonmotor fluctuations: phenotypes, pathophysiology, management, and open issues (2017) (18)
- Physiotherapy improves motor function in patients with the Parkinson variant of multiple system atrophy: A prospective trial. (2019) (18)
- Consistency of “Probable RBD” Diagnosis with the RBD Screening Questionnaire: A Follow‐up Study (2017) (18)
- Seizures and death on a white river float trip. Report of water hemlock poisoning. (1985) (17)
- Is transcranial sonography useful to distinguish drug‐induced parkinsonism from Parkinson's disease? (2012) (17)
- Depression in alpha-synucleinopathies: prevalence, pathophysiology and treatment. (2000) (17)
- New hopes for disease modification in Parkinson's Disease (2020) (17)
- Substantia nigra hyperechogenicity and Parkinson's disease risk in patients with essential tremor (2016) (16)
- Validation of the neurogenic orthostatic hypotension ratio with active standing. (2020) (16)
- Nabilone for non-motor symptoms of Parkinson’s disease: a randomized placebo-controlled, double-blind, parallel-group, enriched enrolment randomized withdrawal study (The NMS-Nab Study) (2019) (16)
- Left-hemispheric predominance of nigrostriatal deficit in isolated REM sleep behavior disorder (2020) (16)
- Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders. (2019) (15)
- Potential of Diffusion Tensor Imaging and Relaxometry for the Detection of Specific Pathological Alterations in Parkinson's Disease (PD) (2015) (15)
- Axial motor clues to identify atypical parkinsonism: A multicentre European cohort study. (2018) (15)
- Limitations of the Unified Multiple System Atrophy Rating Scale as outcome measure for clinical trials and a roadmap for improvement (2021) (15)
- Failure of Neuroprotection by Embryonic Striatal Grafts in a Double Lesion Rat Model of Striatonigral Degeneration (Multiple System Atrophy) (2000) (15)
- Intoxication with riluzole in Huntington’s disease (2001) (15)
- IgLON5 autoimmunity tested negative in patients with progressive supranuclear palsy and corticobasal syndrome. (2017) (15)
- Urinary retention discriminates multiple system atrophy from Parkinson's disease (2019) (15)
- Abnormalities on structural MRI associate with faster disease progression in multiple system atrophy. (2019) (15)
- Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease: A Randomized, Placebo-Controlled, Phase 1 Study (2021) (15)
- The Unified Multiple System Atrophy Rating Scale: Intrarater reliability (2012) (14)
- Novel decision algorithm to discriminate parkinsonism with combined blood and imaging biomarkers. (2020) (14)
- Role and clinical utility of pramipexole extended release in the treatment of early Parkinson’s disease (2012) (14)
- Multiple system atrophy. (1994) (14)
- Multiple system atrophy (2022) (14)
- [Cost of illness and health service patterns in Morbus Parkinson in Austria]. (2009) (14)
- Automated Analysis of Diffusion‐Weighted Magnetic Resonance Imaging for the Differential Diagnosis of Multiple System Atrophy from Parkinson's Disease (2020) (13)
- REM Sleep Behavior Disorder and REM Sleep Without Atonia are More Frequent in Advanced versus Early Parkinson's Disease. (2021) (13)
- Factors associated with impaired quality of life three months after being diagnosed with COVID-19 (2021) (13)
- Neuropathologic changes in Parkinson disease with late onset of dementia. (2003) (12)
- Haste makes waste: Decision making in patients with restless legs syndrome with and without augmentation (2017) (12)
- Diagnostic accuracy of MR planimetry in clinically unclassifiable parkinsonism. (2020) (12)
- Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Positron Emission Tomography Study with [11C]PBR28 and Machine Learning Analysis (2021) (12)
- Nonmotor symptoms in Parkinson’s disease (2013) (12)
- Treatment of psychotic and behavioral symptoms with clozapine, aripiprazole, and reboxetine in a patient with Huntington's disease. (2013) (11)
- Dementia with Lewy bodies and Parkinson disease with dementia (2007) (11)
- European Academy of Neurology/Movement Disorder Society ‐ European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies (2022) (11)
- Trial of Deferiprone in Parkinson's Disease. (2022) (10)
- Minimally clinically important decline in the parkinsonian variant of multiple system atrophy (2016) (10)
- A Modified Progressive Supranuclear Palsy Rating Scale (2021) (10)
- Differenzialdiagnose der Parkinson-Syndrome mittels MRT (2010) (10)
- In Vivo Magnetic Resonance Imaging of Embryonic Neural Grafts in a Rat Model of Striatonigral Degeneration (Multiple System Atrophy) (2000) (10)
- An MDS Evidence‐Based Review on Treatments for Huntington's Disease (2021) (9)
- L01 Sleep in patients with huntington's disease: an interim analysis (2012) (9)
- Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy (2007) (9)
- Drugs to treat autonomic dysfunction in Parkinson's disease (2002) (9)
- Toward disease modification in multiple system atrophy: Pitfalls, bottlenecks, and possible remedies (2016) (9)
- Association of Essential Tremor With Novel Risk Loci (2022) (9)
- Time will tell: Decision making in premanifest and manifest Huntington’s disease (2020) (9)
- Pragmatic Approach on Neuroimaging Techniques for the Differential Diagnosis of Parkinsonisms (2021) (9)
- [Differential diagnosis of parkinsonian syndromes using MRI]. (2010) (8)
- Reflection impulsivity perceptual decision‐making in patients with restless legs syndrome (2018) (8)
- [Predictors of mental and physical quality of life in Huntington's disease]. (2015) (8)
- Towards seeing the visual impairments in Parkinson’s disease: protocol for a multicentre observational, cross-sectional study (2019) (8)
- Prodromal Parkinson's disease: hype or hope for disease-modification trials? (2022) (7)
- Application of the Updated Movement Disorder Society Criteria for Prodromal Parkinson's Disease to a Population‐Based 10‐Year Study (2021) (7)
- Development and Validation of Automated Magnetic Resonance Parkinsonism Index 2.0 to Distinguish Progressive Supranuclear Palsy‐Parkinsonism From Parkinson's Disease (2022) (7)
- Augmentation in restless legs syndrome: an eye tracking study on emotion processing (2020) (7)
- Plasma fasting cholesterol profiles and age at onset in Parkinson's disease (2015) (7)
- Automated segmentation of deep brain nuclei using convolutional neural networks and susceptibility weighted imaging (2021) (7)
- Diagnostic potential of automated tractography in progressive supranuclear palsy variants. (2020) (7)
- Laboratory‐Supported Multiple System Atrophy beyond Autonomic Function Testing and Imaging: A Systematic Review by the MoDiMSA Study Group (2021) (7)
- A Standardized MR Imaging Protocol for Parkinsonism (2020) (6)
- Characterization of gait variability in multiple system atrophy and Parkinson’s disease (2020) (6)
- 1.5 Versus 3 tesla magnetic resonance planimetry in neurodegenerative parkinsonism (2016) (6)
- Application of a Simple Parkinson's Disease Risk Score in a Longitudinal Population‐Based Cohort (2020) (6)
- No effect of age, gender and total intracranial volume on brainstem MR planimetric measurements (2020) (6)
- Treatment of psychosis in Parkinson´s disease (2005) (6)
- Has Deep Brain Stimulation Changed the Very Long‐Term Outcome of Parkinson's Disease? A Controlled Longitudinal Study (2020) (6)
- Overstimulation of the α1B-adrenergic receptor causes a “seizure plus” syndrome (2001) (6)
- Relevance of EARLYSTIM in a tertiary movement disorders center (2014) (5)
- Nonmotor symptoms in Parkinson's (2013) (5)
- Alpha-synuclein seeds in olfactory mucosa of patients with isolated rapid-eye-movement sleep behaviour disorder (2020) (5)
- Characterization and diagnostic potential of diffusion tractography in multiple system atrophy. (2021) (5)
- [Dementia with Lewy bodies]. (2000) (5)
- Topography of cerebral monoamine transporter availability in families with SCA2 mutations: a voxel-wise [123I]β-CIT SPECT analysis (2006) (5)
- Reader response: Olfaction and incident Parkinson disease in US white and black older adults (2018) (5)
- Very late‐onset pure autonomic failure (2017) (4)
- The Frontal Assessment Battery in RLS patients with and without augmentation. (2020) (4)
- Update on Treatments for Motor Symptom of Pd (4)
- Clinical Heterogeneity in Cerebral Hemiatrophy Syndromes (2016) (4)
- Urodynamic Evaluation in Multiple System Atrophy: A Retrospective Cohort Study (2021) (4)
- Differentiating PSP from MSA using MR planimetric measurements: a systematic review and meta-analysis (2021) (4)
- Sensitivity to Change and Patient‐Centricity of the Unified Multiple System Atrophy Rating Scale Items: A Data‐Driven Analysis (2022) (4)
- INTENSIVE CARE MANAGEMENT IN VERY OLD ADULTS: TWO CASES WITH CLOSTRIDIUM TETANI INFECTION (2011) (4)
- Insulin signalling: new target for Parkinson's treatments? (2017) (4)
- Undetected ophthalmological disorders in Parkinson’s disease (2022) (4)
- Effects of self-administered cannabidiol in a patient with multiple system atrophy (2020) (4)
- Birds of a Feather Flock Together: Disadvantageous Decision Making in Augmented Restless Legs Syndrome Patients with and without Impulse Control Disorders (2021) (4)
- Axial myopathy in parkinsonism (2011) (4)
- Topography of Dopamine Transporter Availability in the Cerebellar Variant of Multiple System Atrophy (2017) (4)
- Basal ganglia cellular pathology in multiple system atrophy, progressive supranuclear palsy and Parkinson disease. Can quantitative magnetic resonance spectroscopic imaging make the difference? (2010) (4)
- Substantia nigra hypoechogenicity in Friedreich ataxia (2012) (4)
- Disease-Modifying Therapies for Multiple System Atrophy: Where Are We in 2022? (2022) (3)
- The Unified Multiple System Atrophy Rating Scale: Status, Critique, and Recommendations (2022) (3)
- Impaired Inhibitory Control of Saccadic Eye Movements in Cervical Dystonia: An Eye‐Tracking Study (2021) (3)
- Lewy bodies in patients presenting clinically with Alzheimer disease. (2002) (3)
- Reply: Nonmotor symptoms in subjects without evidence of dopaminergic deficits (2015) (3)
- Diagnosis of drug‐induced parkinsonism: can transcranial sonography make the difference? (2013) (3)
- Synonymous mutation in adenosine triphosphatase copper‐transporting beta causes enhanced exon skipping in Wilson disease (2022) (3)
- Managing the Non‐Motor Symptoms of Parkinson's Disease (2008) (3)
- Symptomatic Care in Multiple System Atrophy: State of the Art (2022) (3)
- Cardiac sympathetic innervation in Parkinson’s disease versus multiple system atrophy (2022) (3)
- A multiplex pedigree with pathologically confirmed multiple system atrophy and Parkinson’s disease with dementia (2022) (3)
- The Parkinson disease connectome — insights from new imaging studies (2021) (3)
- Effects of Nabilone on Sleep Outcomes in Patients with Parkinson's Disease: A Post‐hoc Analysis of NMS‐Nab Study (2022) (3)
- M6 Nabilone in huntington’s disease: a case series of five patients (2016) (3)
- Towards subgroup-specific risk estimates: A meta-analysis of longitudinal studies on olfactory dysfunction and risk of Parkinson's disease. (2021) (3)
- Putaminal diffusion imaging for the differential diagnosis of the parkinsonian variant of multiple system atrophy from Parkinson’s disease: Impact of segmentation accuracy (2017) (2)
- Characterization and diagnostic potential of R2* in early-stage progressive supranuclear palsy variants. (2022) (2)
- Letter re: Incident parkinsonism in older adults without Parkinson disease (2017) (2)
- Associations of Gait Disorders and Recurrent Falls in Older People: A Prospective Population-Based Study (2021) (2)
- Imaging markers of disease progression in multiple system atrophy (2019) (2)
- Transient restless legs syndrome after spinal anesthesia: A prospective study (2002) (2)
- Perimenstrual Fluctuations in Two Siblings With Early‐Onset Parkinson's Disease (2014) (2)
- Impact of coexistent Alzheimer pathology on the natural history of dementia with Lewy bodies (2000) (2)
- Erratum to: The PROMESA-protocol: progression rate of multiple system atrophy under EGCG supplementation as anti-aggregation-approach (2016) (2)
- Distinct smell and taste disorder phenotype of post-acute COVID-19 sequelae (2022) (2)
- [Diagnosis and therapy of multiple system atrophy]. (2001) (2)
- Shaker-related voltage-gated potassium channels Kv1 in human hippocampus (2018) (2)
- Accuracy of diagnosis in dementia with Lewy bodies. (2003) (2)
- Abnormal serotonergic neurotransmission contributes to the pathophysiology of depression in PD (2011) (1)
- Eye Tracking in Patients with Parkinson’s Disease Treated with Nabilone–Results of a Phase II, Placebo-Controlled, Double-Blind, Parallel-Group Pilot Study (2022) (1)
- Disease Primers PARKINSON DISEASE (2017) (1)
- Invasive Treatment Strategies in a Patient with PARK 15–Associated Parkinsonism (2015) (1)
- Tit for Tat: Costly Punishment in Manifest Huntington’s Disease (2021) (1)
- Confusion of Evidence‐Based Reviews and Guidelines (2023) (1)
- Comment on “A series of cases with Huntington-like phenotype and intermediate repeats in HTT” by Acuña and colleagues” (2022) (1)
- Differentiating Parkinson’s Disease from Essential Tremor Using Transcranial Sonography: A Systematic Review and Meta-Analysis (2022) (1)
- Magnetic Resonance Imaging in Movement Disorders: Magnetic resonance imaging of multiple system atrophy (2013) (1)
- The role of arterial spin labeling, a noninvasive MRI perfusion method, in identifying an abnormal cerebral perfusion pattern in Parkinson's disease (2011) (1)
- Modafinil for the Treatment of Daytime Sleepiness in Parkinsons Disease: A Double-blind, Randomized, Crossover, Placebo-controlled Polygraphic Trial NEUROLOGIC DISORDERS (2002) (1)
- An antibody microarray analysis of serum cytokines in neurodegenerative Parkinsonian syndromes (2012) (1)
- Overstimulation of the alpha1B-adrenergic receptor causes a "seizure plus" syndrome. (2001) (1)
- Diagnosis of PSP-P: Can a newly developed MRPI make the difference? (2018) (1)
- The footprint of orthostatic hypotension in parkinsonian syndromes. (2020) (1)
- ‘Advanced’ Parkinson’s disease characteristics in clinical practice: results from the OBSERVE-PD study, a cross-sectional observational study of 2615 patients (P6.001) (2017) (1)
- Family History for Neurodegeneration in Multiple System Atrophy: Does it Indicate Susceptibility? (2022) (1)
- [Atypical Parkinson syndromes--recent advances in diagnosis and therapy]. (2012) (1)
- Structural MRI in Idiopathic Parkinson Disease and Parkinsonism (2013) (1)
- Relationship between the MDS-UPDRS and Quality of Life in Parkinson's Disease: a large international multicenter Study (the QUALPD study) (2016) (1)
- Different assessment tools to detect sarcopenia in patients with Parkinson's disease (2022) (1)
- Orthostatic Hypotension in Parkinson's Disease: Do Height and Weight Matter? (2021) (1)
- Symptomatic hemiparkinsonism due to extensive middle and posterior fossa arachnoid cyst: case report (2020) (1)
- Restless Legs Syndrome and Parkinson's Disease (2010) (1)
- Analysis of sleep, daytime sleepiness and autonomic function and multiple system atrophy and Parkinson disease: a prospective study. (2022) (1)
- Drugs to treat urinary frequency, urgency, and/or urge incontinence (2002) (0)
- Treatment of dementia in Parkinson's disease (2005) (0)
- Temporal Muscle Thickness Correlates with Sarcopenia in Parkinson's Disease. (2023) (0)
- H01 Upcoming international guidelines in huntington’s disease (2018) (0)
- Reply to letter: Nonmotor symptoms in subjects without evidence of dopaminergic deficits (2016) (0)
- Abstracts of the 2021 European Federation of Autonomic Societies (EFAS) Congress (2022) (0)
- Characteristics and medical history in advanced- vs non-advanced Parkinson's disease: an analysis of intercountry differences in the OBSERVE-PD observational study (2020) (0)
- L-DOPA THERAPY IN PARKINSON'S DISEASE: AN UPDATE AFTER 30 YEARS OF CLINICAL USE (2002) (0)
- Clinical Features of 13 Patients with Parkinson's Disease Due to an Autosomal Dominant Mutation in the Vacuolar Protein Sorting-Associated Protein 35 (VPS35) (P01.211) (2012) (0)
- Intercountry differences in dyskinesia in advanced- vs non-advanced Parkinson's disease: a post hoc analysis of the OBSERVE-PD observational study (2020) (0)
- Nomogram to Predict the Probability of Functional Dependence in Early Parkinson’s Disease (2022) (0)
- Impaired functional connectivity of the basal ganglia in idiopathic REM sleep behavior disorder (2017) (0)
- I15 Sleep In Patients With Huntington’s Disease: Interim Results From A Polysomnographic Study (2014) (0)
- Author response for "Time will tell: Decision making in premanifest and manifest Huntington’s disease" (2020) (0)
- Sleep features and long-term incident neurodegeneration: a polysomnographic study (2023) (0)
- Anatomical profile of cognitive impairment in MSA (2016) (0)
- Investigation of Volatile Metabolites in Sebum as Prodromal Indicators of Parkinson’s Disease (2023) (0)
- Patient Concept Elicitation Interviews: Insights into Multiple System Atrophy (MSA) Patient Experiences and Relevance of a modified United Multiple System Atrophy Rating Scale (P8-9.003) (2023) (0)
- Relationship between the MDS-UPDRS and Quality of Life : a large international multicenter study of 3206 patients (2018) (0)
- Nigral Degeneration in Animal Models of Multiple System Atrophy (2000) (0)
- No PD Dyskinesia Scale Protects Against Placebo Responses: A Comparison of Multiple Scales (P04.187) (2013) (0)
- Abstracts of the 6th international multiple system atrophy congress (2018) (0)
- M4 Safety and tolerability of BN82451B in huntington’s disease (2016) (0)
- Anti‐IgLON5 Disease with Isolated Hemichorea: A Case Report and Review of the Literature (2022) (0)
- Multiple system atrophy. (2022) (0)
- Intercountry differences in Parkinson's disease treatment in advanced- vs non-advanced Parkinson's disease: post hoc analysis from the OBSERVE-PD observational study (2020) (0)
- Multiple System Atrophy: Clinical Features and Management (2010) (0)
- Drugs to treat gastrointestinal motility problems (2002) (0)
- Reply to: “Experience with a New Index to Differentiate Parkinson's Disease and Progressive Supranuclear Palsy” (2021) (0)
- Diffusion-weighted MRI differentiates the parkinsonian variant of multiple system atrophy from Parkinsons disease (2001) (0)
- Dorsolateral nigral hyperintensity on 1. 5T vs. 3T susceptibility‐weighted magnetic resonance imaging in neurodegenerative parkinsonism (2023) (0)
- Subject Index Vol. 4, 2007 (2007) (0)
- Orthostatic Hypotension Is Differentially Associated with the Cerebellar Versus the Parkinsonian Variant of Multiple System Atrophy: a Comparative Study (2011) (0)
- Autologous mesenchymal stem cells: Hope for patients with multiple system atrophy? (2019) (0)
- Hospital Admissions of Huntington's Disease Patients in a Huntington's Disease Centre Between 2011 and 2016: A Retrospective Analysis (2022) (0)
- Factors associated with augmentation in patients with restless legs syndrome (2021) (0)
- Disease Progression in Multiple System Atrophy—Novel Modeling Framework and Predictive Factors (2022) (0)
- Extending the Spectrum of Nonmotor Symptoms with Olfaction in Premotor Huntington’s Disease: A Pilot Study (2021) (0)
- Shaker-related voltage-gated potassium channels Kv1 in human hippocampus (2018) (0)
- Glia Imaging Differentiates Multiple System Atrophy from Parkinson's Disease: A Pet Study Using [ 11C ] PBR28 and Machine Learning Enhanced Analysis (2021) (0)
- Forum Report: Asian Scientific Symposium PD and RLS 2008: Neuroimaging for the differential diagnosis of parkinsonism (2009) (0)
- Cognitive dysfunction 1 year after COVID‐19: evidence from eye tracking (2022) (0)
- Confusion of evidence‐based reviews and guidelines (2023) (0)
- Perceptual decision making and reflection impulsivity in drug naive and treated patients with restless legs syndrome (2017) (0)
- Intercountry comparisons of advanced Parkinson's disease symptoms and management: Analysis from the OBSERVE‐PD observational study (2022) (0)
- Health-related quality of life and pharmacotherapy in Parkinson's disease: results of a multi-country study of the EuroPA Study Group (2009) (0)
- α‐Synuclein Seed Amplification Assays in the Diagnosis of Synucleinopathies using Cerebrospinal Fluid – a Systematic Review and Meta‐Analysis (2023) (0)
- Abstracts of the 2022 European Federation of Autonomic Societies (EFAS) Congress (2022) (0)
- Contents Vol. 4, 2007 (2007) (0)
- Reply to “Nonmotor symptoms in subjects without evidence of dopaminergic deficit” authors: “Swallow DMA, Grosset KA, Grosset DG” (2016) (0)
- Psychometric Validation of a Modified United Multiple System Atrophy Rating Scale (S43.002) (2023) (0)
- Contents Vol. 12, 2013 (2013) (0)
- Utility of Nigral Signal Intensity Changes on MR Images to Differentiate Drug-induced Parkinsonism from Parkinson Disease. (2016) (0)
- Reply: “Restless Legs Syndrome and Parkinson's Disease” (2010) (0)
- Comment: Autologous mesenchymal stem cells (2019) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Klaus Seppi?
Klaus Seppi is affiliated with the following schools:
